Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag, Peter Hirth, James Tsai, +37

Nature

Skin CancerMedicineMelanomaClinical EfficacyPharmacology +5

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy

Christian Tovar, James Rosinski, Zoran Filipovic, +10

Proceedings of the National Academy of Sciences

Chemoprevention StrategyApoptosisCell DeathCancer BiologyTumor Biology +15

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Qingjie Ding, Zhuming Zhang, Jinjun Liu, +14

Journal of Medicinal Chemistry

Drug TargetChemical BiologyCancer BiologyPharmaceutical ChemistryP53 Activity +17

RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models

Hong Yang, Brian Higgins, Kenneth Kolinsky, +12

Cancer Research

Melanoma Cell LinesPhase IiMedicineReceptor Tyrosine KinaseMelanoma +13

Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer

Hong Yang, Brian Higgins, Kenneth Kolinsky, +10

Cancer Research

Antitumor ActivityCancer BiologyTumor BiologyProtein Kinase BrafOncology +15

Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation

Fei Su, William D. Bradley, Qiongqing Wang, +18

Cancer Research

Cancer BiologyTumor BiologySignaling PathwayReceptor Tyrosine KinaseKras Protein +14

Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial

Carol M. Moinpour, L. C. Lovato, Mon Oo Yee, +9

JNCI Journal of the National Cancer Institute

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

Brian Higgins, Kenneth Kolinsky, Melissa Smith, +8

Anti-Cancer Drugs

OncologyAntitumor ActivityMedicineTumor Growth InhibitionPathology +10

Forensic Mitochondrial DNA Analysis of 691 Casework Hairs

Terry Melton, Gloria Dimick, Brian Higgins, +2

Journal of Forensic Sciences

Genetic TestingDnaGeneticsDna AnalysisDermatology +14

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma

X. Wilson, Laura Gosa, Veerle W. Daniëls, +16

Nature Medicine

Neuro-oncologyGlucose MetabolismGliomaApoptosisCell Death +8